WO2012134240A2 - 보툴리눔 독소의 동결건조제제 - Google Patents
보툴리눔 독소의 동결건조제제 Download PDFInfo
- Publication number
- WO2012134240A2 WO2012134240A2 PCT/KR2012/002418 KR2012002418W WO2012134240A2 WO 2012134240 A2 WO2012134240 A2 WO 2012134240A2 KR 2012002418 W KR2012002418 W KR 2012002418W WO 2012134240 A2 WO2012134240 A2 WO 2012134240A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- botulinum toxin
- polysorbate
- pharmaceutical
- lyophilized formulation
- methionine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a lyophilized preparation of botulinum toxin that does not contain protein stabilizers derived from animals.
- Botulinum toxin is a polypeptide product of the anaerobic bacterium Clostridium botulinum and is a toxic substance that specifically acts on nerve cells. Botulinum toxin is inherently a toxic substance that causes lethality, but recently, cervical dystonia, blepharospasm, hyperhidrosis, strabismus, achalasia, neurogenic bladder, It is used for the treatment of urological diseases, migraine and the like.
- An example of using such botulinum toxin as a pharmaceutical composition is Meditoxin Co., Ltd., currently sold by the present inventors.
- proteins having a pharmacological effect have a property of adhering to a solid surface, so that when injected into a container, a portion of the protein adheres to the inner wall of the container, resulting in a loss of active ingredient.
- proteins can be easily oxidized or broken down into small fragments, it is necessary to add stabilizers as substances to prevent them.
- albumin albumin
- gelatin gelatin
- albumin reduces the loss of protein active ingredients by reducing protein denaturation that occurs upon adsorption or dilution of proteins when injected into the container.
- Gelatin is a substance obtained by hydrolysis of collagen, which is also used as an alternative to albumin.
- albumin and gelatin are proteins of animal origin, there is a risk of bloodborne pathogens or potential infections.
- stabilizers that do not originate from animals but do not lose the activity of botulinum toxin.
- the present inventors have disclosed a liquid pharmaceutical composition of botulinum toxin including botulinum toxin, methionine, and polysorbate 20, which have long-term stability at room temperature, through Korean Patent Publication No. 2009-0005963.
- the liquid composition is too difficult to maintain the stability of the botulinum toxin at high temperatures above room temperature.
- the present invention aims to provide a lyophilized preparation of botulinum toxin that has a long-term storage stability at high temperature or higher.
- botulinum toxin formulations have been able to maintain the stability of botulinum toxin at refrigerated or at room temperature, but have problems in maintaining the activity of botulinum toxin at high temperatures for a long time. Accordingly, the present inventors have developed a lyophilized preparation of botulinum toxin that maintains its activity for a long time in a wide temperature range including froulin, toxin, room temperature and high temperature, and has excellent storage stability.
- the present invention provides a method for producing a botulinum toxin; 2) polysorbate; 3) methionine; And 4) one or more components selected from the group consisting of sugars, sugar alcohols and ionic compounds.
- the lyophilized preparation of the botulinum toxin according to the present invention is excellent in long-term stability as well as maintaining the activity of the botulinum toxin even at high temperature conditions that may occur during storage, transportation and manipulation of the botulinum toxin.
- the lyophilized preparation of the botulinum toxin according to the present invention comprises 1) botulinum toxin, which was included in the conventional liquid formulation; 2) polysorbate; And 3) at least one selected from the group consisting of 4) sugars, sugar alcohols and ionic compounds as additional components in addition to methionine.
- the additional ingredient serves to stabilize the botulinum toxin when formulated in a lyophilized form while maintaining the activity of the botulinum toxin while maintaining the activity of the botulinum toxin.
- 1) botulinum toxin; 2) polysorbate; And 3) the composition comprising methionine is less stable during lyophilization, and when formulated as a liquid formulation, the stability is lower than room temperature. Not only this was maintained but also long term storage stability.
- Botulinum toxin contained in the freeze-dried preparation according to the invention can be derived from Clostridium botulinum (Clostridium botulinum).
- Clostridium botulinum Clostridium botulinum
- the botulinum toxin included in the lyophilized preparation according to the present invention can be separated and purified from these strains by a known method, or a commercially available product can be used.
- the botulinum toxin included in the lyophilized preparation according to the present invention may be arbitrarily selected from the group consisting of botulinum serotypes A, B, C, D, E, F, and G.
- Botulinum toxin is classified into serotypes A, B, C, D, E, F, and G through immunological differentiation. All of the serotypes of botulinum toxin cause neuronal paralysis by inhibiting the secretion of acetylcholine, a signaling agent in the neuromuscular junction, and the animal species, the degree of paralysis, and the duration of paralysis may vary according to the serotype. It is known.
- the botulinum toxin protein forms various complexes with various hemagglutinin and non-hemagglutinin proteins that assist and protect the action of the botulinum toxin protein.
- the botulinum toxin included in the lyophilized preparation according to the present invention may include both a form containing a complexed protein and a form not containing a complexed protein. The presence of complexed proteins does not affect the activity of botulinum toxin.
- the lyophilized preparation of the botulinum toxin according to the present invention is one of the stabilizers of the botulinum toxin, and polysorbate is a material which is mainly used as an emulsifier in pharmaceutical or food fields as a nonionic surfactant.
- Types of polysorbates include polysorbates 20, 40, 60, 80 or 100 based on the total number of oxyethylene groups. Any lyophilized preparation of the botulinum toxin according to the present invention may be used.
- the polysorbate may be included at 0.01 to 2 mg per 100 units of botulinum toxin. Within this range, not only the activity of botulinum toxin can be maintained even at a high temperature of room temperature or more, and long-term storage stability can be maintained.
- methionine which is one of the stabilizers, is used in place of animal proteins such as albumin and gelatin as stabilizers of botulinum toxin.
- the methionine may be included in 0.01 to 10mg per 100 units of botulinum toxin. Within this range, not only the activity of botulinum toxin can be maintained even at a high temperature of room temperature or more, and long-term storage stability can be maintained.
- the lyophilized preparation of the botulinum toxin according to the present invention unlike conventional liquid formulations, contains at least one sugar, sugar alcohol or ionic compound as an additional component in addition to methionine and polysorbate.
- Sugar is known to protect the denaturation of macromolecules.
- Sugars that can be used in the lyophilized preparations according to the present invention include, but are not limited to, trehalose, sucrose, maltose, fructose, raffinose, lactose (lactose), or glucose (glucose).
- the sugar may be included at 0.1 to 50 mg per 100 units of botulinum toxin. Within this range, not only the activity of botulinum toxin can be maintained even at a high temperature of room temperature or more, and long-term storage stability can be maintained.
- Sugar alcohols are known to be useful for stabilizing polymers and preventing denaturation in liquid or lyophilized conditions.
- Sugar alcohols that can be used in the lyophilized preparations according to the present invention include, but are not limited to, cyclodextrin, mannitol, mannitol, sorbitol, glycerol, xylitol, or inositol. ).
- the sugar alcohol may be included in 0.1 to 50mg per 100 units of botulinum toxin. Within this range, not only the activity of botulinum toxin can be maintained even at a high temperature of room temperature or more, and long-term storage stability can be maintained.
- the ionic compound means a salt (salt) or a buffer (buffer).
- Ionic compounds interact with polymers through specific or nonspecific binding. Salts can increase thermal stability, increase solubility and reduce the degree of aggregation. However, care must be taken at high concentrations of salts, as the protein tends to denature. Ionic compounds include, but are not limited to, sodium chloride, sodium phosphate, ammonium phosphate, magnesium sulfate, sodium acetate, sodium lactate, Sodium succinate, sodium propionate, potassium phosphate, and the like.
- the ionic compound may be included in an amount of 0.1 to 10 mg per 100 units of botulinum toxin. Within this range, not only the activity of botulinum toxin can be maintained even at a high temperature of room temperature or more, and long-term storage stability can be maintained.
- the lyophilized preparation of the botulinum toxin according to the present invention is prepared from, but is not limited to, a culture of Clostridium botulinum cultured in a particular medium.
- the botulinum toxin complex is purified into a crystalline complex consisting of the active high molecular weight toxin protein and the associated hemagglutinin protein through a series of acid precipitations from the culture solution.
- a lyophilized preparation of botulinum toxin is prepared by dissolving a crystalline complex in a solution containing saline and a stabilizer and freeze drying.
- the botulinum toxin lyophilized preparation of the present invention was prepared by lyophilizing sterile preparations containing botulinum toxin, methionine and polysorbate, and sugars or sugar alcohols and / or ionic compounds.
- Stability of botulinum toxin was determined as the continuation of activity after a certain storage period, and the continuation of the activity of botulinum toxin was measured by mouse LD 50 or mouse mortality.
- the lyophilized formulation was stored at 40 ° C. and 70% relative humidity for 30 days, dissolved in physiological drinking water, and injected with botulinum toxin, equivalent to 2.5 LD 50 IU, into the abdominal cavity of three mice, at least two of which were killed. In this case, it was determined that stability was maintained, which is expressed as mortality in the table below. If the mortality rate of the mouse is 50% or more can be assessed to maintain the activity of the botulinum toxin.
- Activity test is carried out as follows. 2.8 mL of physiological saline was added to the vial of sample 2 and dissolved. 4.4 mL of this solution was taken as 1.45 mL of saline solution as sample solution 1. 4.4 mL of sample solution 1 was added to 1.45 mL of saline solution as sample solution 2. Diluted eight times in the same manner, each was used as a test liquid. Samples from sample 3 to sample 6 were injected into 17-22 g mice (CD1, female) in 10 abdominal cavity per sample and 0.1 mL per horse, and after 3 days, mortality was measured and statistically treated by Probit method. LD 50 was obtained to obtain the titer.
- Stabilizers capable of replacing human serum albumin were selected from a combination of human serum albumin and polysorbate, which are components of a stabilizer of a known botulinum toxin.
- Table 1 Composition of liquid preparations % Death after 30 days storage Polysorbate 20 (mg / mL) Botulinum Toxin (unit / mL) Stabilizer (Concentration) 2 100 - 0 HSA (5mg / mL) 100 L-Methionine (20mM) 100 L-arginine (50mM) 0 Histidine (10 mM) 0 Mannitol (50mg / mL) 0 Sorbitol (50mg / mL) 0 Sucrose (50mg / mL) 0 Lactose (50 mg / mL) 0
- Table 2 shows the stability test results (% mortality) of botulinum toxin at various concentrations of methionine and polysorbate 20 when stored for 30 days, and Table 3 shows various results of methionine and polysorbate 20 when stored for 60 days. Stability test results (% mortality) of botulinum toxin at concentration conditions are shown. The concentration of botulinum toxin in the botulinum toxin liquid composition of the experiment was 100 units / mL.
- the stabilizing effect of botulinum toxin does not last, but at least one of sugar, sugar alcohol and ionic compound is added to methionine and polysorbate. When it was confirmed that the stabilization effect is maintained.
- Table 5 Composition of Lyophilized Preparation % Mortality after 30 days storage
- Botulinum Toxin + Methionine + Polysorbate 20 Additional stabilizer content Sucrose 0.3mg 100 2.0mg 100 4.0mg 100 50 mg 100 Trehalose 0.3mg 100 2.0mg 100 Sorbitol 40mg 100 Mannitol 40mg 100 Sodium chloride 0.06mg 0 0.1mg 100 0.3mg 100 0.6mg 100 0.9mg 100 1.2mg 100 10mg 100 Sodium phosphate Sodium dihydrogen phosphate 0.05mg 100 Sodium Dihydrogen Phosphate Dihydrate 0.101mg
- Table 6 Composition of Lyophilized Preparation Unit 0 main role 2-week potency 4-week potency 8-week potency 12-week potency 24 week potency Botulinum Toxin + Human Serum Albumin + Sodium Chloride - 0 0 - - - Botulinum Toxin + Methionine + Polysorbate 20 + Sodium Phosphate (Sodium Chloride) + Sucrose 109 (120) 100 (95) 80 (95) 100 (120) 95 103
- the present invention is directed to twitching (cervical dystonia), blepharospasm, hyperhidrosis, strabismus, achalasia, neurogenic bladder, urologic disease, migraine ) Can be used as a therapeutic agent.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
액상 제제의 조성 | 30일 보관 후 사망률(%) | ||
폴리솔베이트 20(mg/mL) | 보툴리눔 독소(unit/mL) | 안정화제(농도) | |
2 | 100 | - | 0 |
HSA (5mg/mL) | 100 | ||
L-메티오닌 (20mM) | 100 | ||
L-아르기닌 (50mM) | 0 | ||
히스티딘 (10mM) | 0 | ||
만니톨 (50mg/mL) | 0 | ||
소르비톨 (50mg/mL) | 0 | ||
수크로오스 (50mg/mL) | 0 | ||
락토오스 (50mg/mL) | 0 |
농도 | 메티오닌(mM) | |||||||
1 | 5 | 10 | 25 | 50 | 75 | 100 | ||
폴리솔베이트 20 (mg/mL) | 0.1 | 100 | 100 | 80 | 100 | 100 | 100 | 100 |
0.5 | 100 | 100 | 80 | 100 | 100 | 100 | 100 | |
2.5 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
10 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
20 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
25 | 80 | 100 | 100 | 80 | 80 | 100 | 100 |
농도 | 메티오닌(mM) | |||||||
1 | 5 | 10 | 25 | 50 | 75 | 100 | ||
폴리솔베이트 20 (mg/mL) | 0.1 | 100 | 100 | 80 | 100 | 100 | 80 | 100 |
0.5 | 100 | 100 | 80 | 100 | 100 | 100 | 100 | |
2.5 | 100 | 100 | 100 | 80 | 100 | 100 | 100 | |
10 | 0 | 40 | 0 | 100 | 100 | 100 | 40 | |
20 | 0 | 80 | 80 | 100 | - | 100 | 60 | |
25 | 0 | 0 | 0 | 0 | 80 | - | 0 |
동결건조제제의 조성 | 30일 보관 후 사망률(%) | |||||
보툴리눔 독소 +메티오닌 +폴리솔베이트 20 | 추가 안정화제 | |||||
염화나트륨 | 인산나트륨 | 수크로오스 | 만니톨 | 소르비톨 | ||
- | - | - | - | - | 0 | |
0.9mg | - | - | - | - | 100 | |
- | 10mM | - | - | - | 100 | |
- | - | 0.3mg | - | - | 100 | |
- | - | - | 40mg | - | 100 | |
0.9mg | - | - | 40mg | - | 100 | |
- | 10mM | - | 40mg | - | 100 | |
- | 10mM | 50mg | - | - | 100 | |
0.9mg | - | 50mg | - | - | 100 | |
- | 10mM | 50mg | - | 40mg | 100 |
동결건조제제의 조성 | 30일 보관후 사망률(%) | |||
보툴리눔 독소 +메티오닌 +폴리솔베이트 20 | 추가 안정화제 | 함량 | ||
수크로오스 | 0.3mg | 100 | ||
2.0mg | 100 | |||
4.0mg | 100 | |||
50mg | 100 | |||
트레할로스 | 0.3mg | 100 | ||
2.0mg | 100 | |||
소르비톨 | 40mg | 100 | ||
만니톨 | 40mg | 100 | ||
염화나트륨 | 0.06mg | 0 | ||
0.1mg | 100 | |||
0.3mg | 100 | |||
0.6mg | 100 | |||
0.9mg | 100 | |||
1.2mg | 100 | |||
10mg | 100 | |||
인산나트륨 | 무수인산일수소나트륨 | 0.05mg | 100 | |
인산이수소나트륨이수화물 | 0.101mg |
동결건조제제의 조성 | 역가(unit) | |||||
0주역가 | 2주 역가 | 4주 역가 | 8주 역가 | 12주 역가 | 24주 역가 | |
보툴리눔 독소+인간혈청알부민+ 염화나트륨 | - | 0 | 0 | - | - | - |
보툴리눔 독소+메티오닌+폴리솔베이트20+인산나트륨(염화나트륨)+수크로오스 | 109(120) | 100(95) | 80(95) | 100(120) | 95 | 103 |
Claims (12)
- 보툴리눔 독소, 폴리솔베이트 및 메티오닌; 및당, 당 알코올 및 이온 화합물로 이루어진 군으로부터 선택된 하나 이상의 성분을 포함하는 약제학적 동결건조제제.
- 제1항에 있어서,보툴리눔 독소는 보툴리눔 세로타입(serotype) A, B, C, D, E, F 및 G로 이루어진 군으로부터 선택된 것인 약제학적 동결건조제제.
- 제1항에 있어서,보툴리눔 독소는 복합체화 단백질을 함유하지 않는 형태 또는 복합체와 단백질을 함유하는 복합체 형태인 약제학적 동결건조제제.
- 제1항에 있어서,폴리솔베이트는 폴리솔베이트 20, 40, 60, 80 또는 100 중 어느 하나인 약제학적 동결건조제제.
- 제1항에 있어서,폴리솔베이트는 보툴리눔 독소 100 유닛당 0.01 내지 2mg으로 포함되는 약제학적 동결건조제제.
- 제1항에 있어서,메티오닌은 보툴리눔 독소 100 유닛당 0.01 내지 10mg으로 포함되는 약제학적 동결건조제제.
- 제1항에 있어서,당은 트레할로스(trehalose), 수크로오스(sucrose), 말토오스(maltose), 프럭토오스(fluctose), 라피노오스(lapinose), 락토오스(lactose) 및 글루코오스(glucose)로 이루어진 군으로부터 선택된 하나 이상인 약제학적 동결건조제제.
- 제1항에 있어서,당은 보툴리눔 독소 100 유닛당 0.1 내지 50mg으로 포함되는 약제학적 동결건조제제.
- 제1항에 있어서,당 알코올은 사이클로덱스트린(cylodextrin), 만니톨(mannitol), 소르비톨(sorbitol), 글리세롤(glycerol), 자일리톨(xylitol) 및 이노시톨(inositol)로 이루어진 군으로부터 선택된 하나 이상인 약제학적 동결건조제제.
- 제1항에 있어서,당 알코올은 보툴리눔 독소 100 유닛당 0.1 내지 50mg으로 포함되는 약제학적 동결건조제제.
- 제1항에 있어서,이온 화합물은 염화나트륨(sodium chloride), 인산나트륨(sodium phosphate), 인산암모늄(ammonium phosphate), 황산마그네슘(magnesium sulfate), 아세트산나트륨(sodium acetate), 젖산나트륨(sodium lactate), 숙신산나트륨(sodium succinate), 프로피온산나트륨(sodium propionate) 및 인산칼륨(potassium phosphate)으로 이루어진 군으로부터 선택된 하나 이상인 약제학적 동결건조제제.
- 제1항에 있어서,이온 화합물은 보툴리눔 독소 100 유닛당 0.1 내지 10mg으로 포함되는 약제학적 동결건조제제.
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK12765216.2T DK2692350T4 (da) | 2011-03-31 | 2012-03-30 | Lyofiliseret præparat af botulinumtoksin |
US14/008,326 US8920795B2 (en) | 2011-03-31 | 2012-03-30 | Lyophilized preparation of botulinum toxin |
ES12765216T ES2636680T5 (es) | 2011-03-31 | 2012-03-30 | Preparación liofilizada de toxina botulínica |
BR112013025256-1A BR112013025256B1 (pt) | 2011-03-31 | 2012-03-30 | Preparação liofilizada farmacêutica |
CA2831908A CA2831908C (en) | 2011-03-31 | 2012-03-30 | Lyophilized preparation of botulinum toxin |
EP12765216.2A EP2692350B2 (en) | 2011-03-31 | 2012-03-30 | Lyophilized preparation of botulinum toxin |
MX2013011119A MX338436B (es) | 2011-03-31 | 2012-03-30 | Preparacion liofilizada de toxinas de botulismo. |
MX2016004606A MX355771B (es) | 2011-03-31 | 2012-03-30 | Preparacion liofilizada de toxinas de botulismo. |
RU2013148119/15A RU2574011C2 (ru) | 2011-03-31 | 2012-03-30 | Лиофилизированный препарат ботулотоксина |
AU2012233845A AU2012233845B2 (en) | 2011-03-31 | 2012-03-30 | Lyophilized preparation of botulinum toxin |
PL12765216.2T PL2692350T5 (pl) | 2011-03-31 | 2012-03-30 | Liofilizowany preparat toksyny botulinowej |
EP17168989.6A EP3241547B1 (en) | 2011-03-31 | 2012-03-30 | Lyophilized preparation of botulinum toxin |
JP2014502485A JP5826914B2 (ja) | 2011-03-31 | 2012-03-30 | ボツリヌム毒素の凍結乾燥製剤 |
PL17168989T PL3241547T3 (pl) | 2011-03-31 | 2012-03-30 | Liofilizowany preparat toksyny botulinowej |
CN201280016784.6A CN103596580A (zh) | 2011-03-31 | 2012-03-30 | 肉毒杆菌毒素冻干制剂 |
SG2013073622A SG194039A1 (en) | 2011-03-31 | 2012-03-30 | Lyophilized preparation of botulinum toxin |
EP20172705.4A EP3756656B1 (en) | 2011-03-31 | 2012-03-30 | Lyophilized preparation of botulinum toxin |
IL228607A IL228607B (en) | 2011-03-31 | 2013-09-29 | A preparation of lyophilized botulinum toxins |
ZA2013/08115A ZA201308115B (en) | 2011-03-31 | 2013-10-30 | Lyophilized preparation of botulinum toxin |
US14/533,735 US9198958B2 (en) | 2011-03-31 | 2014-11-05 | Lyophilized preparation of botulinum toxin |
US14/954,261 US20160089442A1 (en) | 2011-03-31 | 2015-11-30 | Lyophilized Preparation of Botulinum Toxin |
AU2016201040A AU2016201040B2 (en) | 2011-03-31 | 2016-02-19 | Lyophilized preparation of botulinum toxin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110029577 | 2011-03-31 | ||
KR10-2011-0029577 | 2011-03-31 | ||
KR1020120033374A KR101395064B1 (ko) | 2011-03-31 | 2012-03-30 | 보톨리눔 독소의 동결건조제제 |
KR10-2012-0033374 | 2012-03-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/008,326 A-371-Of-International US8920795B2 (en) | 2011-03-31 | 2012-03-30 | Lyophilized preparation of botulinum toxin |
US14/533,735 Continuation US9198958B2 (en) | 2011-03-31 | 2014-11-05 | Lyophilized preparation of botulinum toxin |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012134240A2 true WO2012134240A2 (ko) | 2012-10-04 |
WO2012134240A3 WO2012134240A3 (ko) | 2013-01-03 |
Family
ID=47282510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/002418 WO2012134240A2 (ko) | 2011-03-31 | 2012-03-30 | 보툴리눔 독소의 동결건조제제 |
Country Status (22)
Country | Link |
---|---|
US (3) | US8920795B2 (ko) |
EP (3) | EP3756656B1 (ko) |
JP (3) | JP5826914B2 (ko) |
KR (1) | KR101395064B1 (ko) |
CN (2) | CN103596580A (ko) |
AU (2) | AU2012233845B2 (ko) |
BR (1) | BR112013025256B1 (ko) |
CA (1) | CA2831908C (ko) |
CO (1) | CO6821888A2 (ko) |
DK (2) | DK3241547T3 (ko) |
ES (2) | ES2810098T3 (ko) |
HK (1) | HK1246174A1 (ko) |
HU (1) | HUE050037T2 (ko) |
IL (1) | IL228607B (ko) |
MX (2) | MX338436B (ko) |
PL (2) | PL2692350T5 (ko) |
PT (1) | PT3241547T (ko) |
RU (2) | RU2574011C2 (ko) |
SG (3) | SG194039A1 (ko) |
SI (1) | SI3241547T1 (ko) |
WO (1) | WO2012134240A2 (ko) |
ZA (1) | ZA201308115B (ko) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160256532A1 (en) * | 2009-06-25 | 2016-09-08 | Revance Therapeutics, Inc. | Albumin-Free Botulinum Toxin Formulations |
JP2016540785A (ja) * | 2013-12-12 | 2016-12-28 | メディ−トックス インク | 新しいボツリヌス毒素製剤の長期持続作用 |
WO2020169578A1 (en) | 2019-02-21 | 2020-08-27 | Merz Pharma Gmbh & Co. Kgaa | Novel uses of botulinum neurotoxin for the treatment of tremor |
US10973890B2 (en) | 2016-09-13 | 2021-04-13 | Allergan, Inc. | Non-protein clostridial toxin compositions |
WO2022019584A1 (ko) | 2020-07-23 | 2022-01-27 | (주)메디톡스 | 암 치료제 |
US11471708B2 (en) | 2008-12-31 | 2022-10-18 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations |
WO2023277433A1 (ko) | 2021-06-28 | 2023-01-05 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
WO2023277432A1 (ko) | 2021-06-28 | 2023-01-05 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2266600B1 (en) * | 2004-07-26 | 2014-09-10 | Merz Pharma GmbH & Co. KGaA | Therapeutic composition with a botulinum neurotoxin |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
CN101687046B (zh) * | 2007-07-10 | 2012-12-26 | 株式会社美地拓斯 | 稳定性改善的肉毒毒素药物液体组合物 |
PT3241547T (pt) * | 2011-03-31 | 2020-08-26 | Medy Tox Inc | Preparação liofilizada de toxina botulínica |
JP6643324B2 (ja) | 2014-09-02 | 2020-02-12 | アメリカン シルヴァー リミテッド ライアビリティ カンパニー | ボツリヌス毒素及びコロイド状銀粒子 |
US20180200325A1 (en) * | 2014-11-18 | 2018-07-19 | Shionogi & Co., Ltd. | Stabilized peptide composition |
KR101737387B1 (ko) | 2015-06-01 | 2017-05-18 | 유용우 | 2차 발효 홍삼을 이용한 건강기능식품의 제조방법 |
KR20180114891A (ko) * | 2016-03-02 | 2018-10-19 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소를 포함하는 조성물 |
KR101744900B1 (ko) | 2017-01-20 | 2017-06-08 | 주식회사 대웅 | 보툴리눔 독소를 포함하는 안정한 액상 조성물 |
CN107540732B (zh) * | 2017-08-31 | 2020-07-14 | 青海省畜牧兽医科学院 | 一种d型肉毒毒素的仿生矿化加工方法及应用 |
KR101968873B1 (ko) * | 2018-09-21 | 2019-04-29 | 아이큐어 주식회사 | 세포 침투 효과가 우수한 보툴리늄 유래 펩타이드를 포함하는 화장료 조성물 |
WO2020111852A1 (ko) * | 2018-11-30 | 2020-06-04 | 주식회사 휴온스글로벌 | 보툴리눔 독소의 안정화 액상 조성물 |
KR102259423B1 (ko) * | 2018-11-30 | 2021-06-02 | 주식회사 휴온스바이오파마 | 보툴리눔 독소의 안정화 액상 조성물 |
CN110637814B (zh) * | 2019-10-22 | 2021-11-19 | 青海省畜牧兽医科学院 | 一种d型肉毒毒素的微囊化制备方法 |
WO2021086123A1 (ko) * | 2019-10-31 | 2021-05-06 | 휴젤㈜ | 보툴리눔 독소에 대한 마이크로 구조체 제형화 기술 |
KR102414997B1 (ko) * | 2020-09-29 | 2022-06-29 | 주식회사 엘지생활건강 | 안정성이 개선된 재조합 보툴리눔 독소 경쇄 단백질 조성물 |
KR20220114183A (ko) * | 2021-02-08 | 2022-08-17 | 주식회사 대웅 | 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물 |
KR102427362B1 (ko) | 2021-11-11 | 2022-08-01 | (주)이니바이오 | 보툴리눔 독소 제제의 건조 공정 |
CA3238234A1 (en) * | 2021-11-15 | 2023-05-19 | Medytox Inc. | Botulinum neurotoxin composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090005963A (ko) | 2007-07-10 | 2009-01-14 | (주)메디톡스 | 보툴리눔 독소의 안정성이 개선된 약제학적 액상 조성물 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US20030118598A1 (en) † | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
DE60125986T3 (de) * | 2000-02-08 | 2011-07-28 | Allergan, Inc., 92612, Calif. | Pharmazeutische Zusammensetzungen mit Botulinum Toxin |
DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
GB2416122A (en) † | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
CN101175478A (zh) * | 2005-10-06 | 2008-05-07 | 阿勒根公司 | 非蛋白稳定的梭菌毒素药物组合物 |
CN101720331A (zh) * | 2007-06-01 | 2010-06-02 | 德国麦氏大药厂 | 基于肉毒毒素的神经毒成分供应温度-稳定性肌肉松弛剂的方法 |
EP2373294B1 (en) * | 2008-12-10 | 2016-04-20 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
KR101135449B1 (ko) * | 2009-03-10 | 2012-04-13 | 한국과학기술연구원 | 헤파라나제 활성 측정용 이온 복합체 나노 입자 및 그 제조방법 |
EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
PT3241547T (pt) * | 2011-03-31 | 2020-08-26 | Medy Tox Inc | Preparação liofilizada de toxina botulínica |
US20130236446A1 (en) * | 2012-03-12 | 2013-09-12 | William J. Binder | Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth |
-
2012
- 2012-03-30 PT PT171689896T patent/PT3241547T/pt unknown
- 2012-03-30 BR BR112013025256-1A patent/BR112013025256B1/pt active IP Right Grant
- 2012-03-30 SI SI201231811T patent/SI3241547T1/sl unknown
- 2012-03-30 CN CN201280016784.6A patent/CN103596580A/zh active Pending
- 2012-03-30 SG SG2013073622A patent/SG194039A1/en unknown
- 2012-03-30 EP EP20172705.4A patent/EP3756656B1/en active Active
- 2012-03-30 US US14/008,326 patent/US8920795B2/en active Active
- 2012-03-30 CA CA2831908A patent/CA2831908C/en active Active
- 2012-03-30 JP JP2014502485A patent/JP5826914B2/ja active Active
- 2012-03-30 ES ES17168989T patent/ES2810098T3/es active Active
- 2012-03-30 RU RU2013148119/15A patent/RU2574011C2/ru active
- 2012-03-30 AU AU2012233845A patent/AU2012233845B2/en active Active
- 2012-03-30 EP EP12765216.2A patent/EP2692350B2/en active Active
- 2012-03-30 ES ES12765216T patent/ES2636680T5/es active Active
- 2012-03-30 MX MX2013011119A patent/MX338436B/es active IP Right Grant
- 2012-03-30 DK DK17168989.6T patent/DK3241547T3/da active
- 2012-03-30 PL PL12765216.2T patent/PL2692350T5/pl unknown
- 2012-03-30 HU HUE17168989A patent/HUE050037T2/hu unknown
- 2012-03-30 CN CN201910264812.XA patent/CN109925284A/zh active Pending
- 2012-03-30 KR KR1020120033374A patent/KR101395064B1/ko active IP Right Grant
- 2012-03-30 MX MX2016004606A patent/MX355771B/es unknown
- 2012-03-30 DK DK12765216.2T patent/DK2692350T4/da active
- 2012-03-30 RU RU2015150422A patent/RU2640922C1/ru active
- 2012-03-30 WO PCT/KR2012/002418 patent/WO2012134240A2/ko active Application Filing
- 2012-03-30 SG SG10202013124XA patent/SG10202013124XA/en unknown
- 2012-03-30 PL PL17168989T patent/PL3241547T3/pl unknown
- 2012-03-30 SG SG10201605324PA patent/SG10201605324PA/en unknown
- 2012-03-30 EP EP17168989.6A patent/EP3241547B1/en active Active
-
2013
- 2013-09-29 IL IL228607A patent/IL228607B/en active IP Right Grant
- 2013-10-29 CO CO13256647A patent/CO6821888A2/es not_active Application Discontinuation
- 2013-10-30 ZA ZA2013/08115A patent/ZA201308115B/en unknown
-
2014
- 2014-11-05 US US14/533,735 patent/US9198958B2/en active Active
-
2015
- 2015-10-14 JP JP2015202730A patent/JP6005239B2/ja active Active
- 2015-11-30 US US14/954,261 patent/US20160089442A1/en not_active Abandoned
-
2016
- 2016-02-19 AU AU2016201040A patent/AU2016201040B2/en active Active
- 2016-09-06 JP JP2016173874A patent/JP6173547B2/ja active Active
-
2018
- 2018-05-03 HK HK18105697.5A patent/HK1246174A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090005963A (ko) | 2007-07-10 | 2009-01-14 | (주)메디톡스 | 보툴리눔 독소의 안정성이 개선된 약제학적 액상 조성물 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11471708B2 (en) | 2008-12-31 | 2022-10-18 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations |
US11351232B2 (en) | 2009-06-25 | 2022-06-07 | Revance Therapeutics, Inc. | Albumin-free botulinum toxin formulations |
US11911449B2 (en) | 2009-06-25 | 2024-02-27 | Revance Therapeutics, Inc. | Albumin-free botulinum toxin formulations |
US10111939B2 (en) * | 2009-06-25 | 2018-10-30 | Revance Therapeutics, Inc. | Albumin-free botulinum toxin formulations |
US20160256532A1 (en) * | 2009-06-25 | 2016-09-08 | Revance Therapeutics, Inc. | Albumin-Free Botulinum Toxin Formulations |
JP2022161932A (ja) * | 2013-12-12 | 2022-10-21 | メディトックス インク. | 新しいボツリヌス毒素製剤の長期持続作用 |
EP3079714B1 (en) | 2013-12-12 | 2020-11-25 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
AU2020203349B2 (en) * | 2013-12-12 | 2022-06-16 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
JP7121458B2 (ja) | 2013-12-12 | 2022-08-18 | メディトックス インク. | 新しいボツリヌス毒素製剤の長期持続作用 |
JP2020045360A (ja) * | 2013-12-12 | 2020-03-26 | メディ−トックス インク | 新しいボツリヌス毒素製剤の長期持続作用 |
JP2016540785A (ja) * | 2013-12-12 | 2016-12-28 | メディ−トックス インク | 新しいボツリヌス毒素製剤の長期持続作用 |
JP7439187B2 (ja) | 2013-12-12 | 2024-02-27 | メディトックス インク. | 新しいボツリヌス毒素製剤の長期持続作用 |
US10973890B2 (en) | 2016-09-13 | 2021-04-13 | Allergan, Inc. | Non-protein clostridial toxin compositions |
WO2020169578A1 (en) | 2019-02-21 | 2020-08-27 | Merz Pharma Gmbh & Co. Kgaa | Novel uses of botulinum neurotoxin for the treatment of tremor |
WO2022019584A1 (ko) | 2020-07-23 | 2022-01-27 | (주)메디톡스 | 암 치료제 |
WO2023277433A1 (ko) | 2021-06-28 | 2023-01-05 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
WO2023277432A1 (ko) | 2021-06-28 | 2023-01-05 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012134240A2 (ko) | 보툴리눔 독소의 동결건조제제 | |
EP1220685B1 (en) | Pharmaceutical compositions of fibrinolytic agent | |
US20210145941A1 (en) | Pharmaceutical compositions for treating acid sphingomyelinase deficiency | |
EP1997509A1 (en) | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin | |
WO2022071671A1 (ko) | 안정성이 개선된 재조합 보툴리눔 독소 경쇄 단백질 조성물 | |
AU2004201694B2 (en) | Pharmaceutical compositions of fibrinolytic agent | |
AU2006200638B2 (en) | Pharmaceutical compositions of fibrinolytic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12765216 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/011119 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2014502485 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2831908 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1301005634 Country of ref document: TH |
|
REEP | Request for entry into the european phase |
Ref document number: 2012765216 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012765216 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13256647 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2012233845 Country of ref document: AU Date of ref document: 20120330 Kind code of ref document: A Ref document number: 2013148119 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14008326 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013025256 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013025256 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130930 |